AstraZeneca spins off autoimmune drugs into new biotech company

LONDON (Reuters) - AstraZeneca is spinning off six early-stage experimental drugs into a new $250 million standalone biotech company focused on severe autoimmune diseases.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news